The invention also concerns the cryoprecipitated suspension, the fibrin glue formed therefrom, fibrin glue kits and a method for sealing surgical wounds.

A further aspect of the invention relates to the use of a thrombin solution in a component for a fibrin glue.

Its crosslinking technology generates a strong and safe adhesive fibrin sealant required for high volume hemostasis.

The dry powder compositions may be fibrin sealant compositions comprising fibrinogen and/or thrombin.

One studied fibrin sealant, and the other 16 studied HA.

Cell therapy may be combined with the injection of fibrin glue or other injectable polymer scaffold agent.

An applicator for dispensing a first and second component of a biological adhesive, such as fibrin glue.

The material may be a non-living agent, such as a polymer agent, e.g. fibrin glue agent or collagen agent.

Such a fibrin glue composition can be placed directly on a wound site and is fully reabsorbed into the body.

The invention also comprises a biosealant for use with the fibrin glue without fibrinogen or for use alone.

Biologic plugs and fibrin glue instillations are alternatives to surgery.

No evidence was found of a treatment effect of fibrin sealant as an adherence compound.

Alternatively, synthetically produced fibrin glue or other sealants can be utilized in a method of sealing an arteriotomy site.

The present invention describes a biologically compatible bioadhesive sealant composition comprising fibrin glue and liposomes for use in mammals, including humans.

Long-lasting biophysical and biomechanical properties as well as therapeutic value are imparted to the fibrin glue components by the liposome component of the composition.